0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lung cancer risk prediction models based on pulmonary nodules: A systematic review

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Screening with low‐dose computed tomography (LDCT) is an efficient way to detect lung cancer at an earlier stage, but has a high false‐positive rate. Several pulmonary nodules risk prediction models were developed to solve the problem. This systematic review aimed to compare the quality and accuracy of these models.

          Methods

          The keywords “lung cancer,” “lung neoplasms,” “lung tumor,” “risk,” “lung carcinoma” “risk,” “predict,” “assessment,” and “nodule” were used to identify relevant articles published before February 2021. All studies with multivariate risk models developed and validated on human LDCT data were included. Informal publications or studies with incomplete procedures were excluded. Information was extracted from each publication and assessed.

          Results

          A total of 41 articles and 43 models were included. External validation was performed for 23.2% (10/43) models. Deep learning algorithms were applied in 62.8% (27/43) models; 60.0% (15/25) deep learning based researches compared their algorithms with traditional methods, and received better discrimination. Models based on Asian and Chinese populations were usually built on single‐center or small sample retrospective studies, and the majority of the Asian models (12/15, 80.0%) were not validated using external datasets.

          Conclusion

          The existing models showed good discrimination for identifying high‐risk pulmonary nodules, but lacked external validation. Deep learning algorithms are increasingly being used with good performance. More researches are required to improve the quality of deep learning models, particularly for the Asian population.

          Abstract

          Pulmonary nodules risk prediction models were developed to reduce the high false‐positive rate of lung cancer screening. A total of 41 articles and 43 models were systematically identified and assessed. The existing models showed good discrimination, but lacked external validation. Deep learning algorithms were increasingly being used with good performance. More researches were required to improve the quality of deep learning models, particularly for the Asian population.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Deep learning.

            Deep learning allows computational models that are composed of multiple processing layers to learn representations of data with multiple levels of abstraction. These methods have dramatically improved the state-of-the-art in speech recognition, visual object recognition, object detection and many other domains such as drug discovery and genomics. Deep learning discovers intricate structure in large data sets by using the backpropagation algorithm to indicate how a machine should change its internal parameters that are used to compute the representation in each layer from the representation in the previous layer. Deep convolutional nets have brought about breakthroughs in processing images, video, speech and audio, whereas recurrent nets have shone light on sequential data such as text and speech.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reduced lung-cancer mortality with low-dose computed tomographic screening.

              (2011)
              The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer. From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02). Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385.).
                Bookmark

                Author and article information

                Contributors
                tanfengwei@cicams.ac.cn
                nli@cicams.ac.cn
                hejie@cicams.ac.cn
                Journal
                Thorac Cancer
                Thorac Cancer
                10.1111/(ISSN)1759-7714
                TCA
                Thoracic Cancer
                John Wiley & Sons Australia, Ltd (Melbourne )
                1759-7706
                1759-7714
                08 February 2022
                March 2022
                : 13
                : 5 ( doiID: 10.1111/tca.v13.5 )
                : 664-677
                Affiliations
                [ 1 ] Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
                [ 2 ] Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
                [ 3 ] PET‐CT Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
                [ 4 ] Department of Epidemiology, Center for Global Health, School of Public Health Nanjing Medical University Nanjing China
                [ 5 ] Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing China
                [ 6 ] Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
                [ 7 ] Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
                Author notes
                [*] [* ] Correspondence

                Fengwei Tan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.

                Email: tanfengwei@ 123456cicams.ac.cn

                Ni Li, Office of Cancer Screening, National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement; No.17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.

                Email: nli@ 123456cicams.ac.cn

                Jie He, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.

                Email: hejie@ 123456cicams.ac.cn

                Author information
                https://orcid.org/0000-0002-8210-684X
                https://orcid.org/0000-0001-5530-7745
                https://orcid.org/0000-0002-0285-5403
                Article
                TCA14333
                10.1111/1759-7714.14333
                8888150
                35137543
                d2308e42-9e1c-4232-81f9-6b682b6bd2f1
                © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 10 January 2022
                : 06 November 2021
                : 11 January 2022
                Page count
                Figures: 4, Tables: 6, Pages: 14, Words: 8751
                Funding
                Funded by: National Key Research and Development Program of China , doi 10.13039/501100012166;
                Award ID: 2018YFC1315000
                Funded by: National Natural Science Foundation of China , doi 10.13039/501100001809;
                Award ID: 8187102812
                Funded by: Non‐profit Central Research Institute Fund of Chinese Academy of Medical Sciences
                Award ID: 2018RC320010
                Award ID: 2019PT320027
                Award ID: 2019PT320023
                Award ID: 2020‐PT330‐001
                Award ID: 3332019005
                Categories
                Review
                Review
                Custom metadata
                2.0
                March 2022
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.2 mode:remove_FC converted:01.03.2022

                early detection and early diagnosis,lung cancer,prediction,pulmonary nodule,screening

                Comments

                Comment on this article